New York, NY -- (SBWIRE) -- 06/12/2017 -- In Vitro Diagnostics (IVD) Market:

Executive Summary

In-vitro diagnostic is a process in which reagents, instruments, and systems are intended for the diagnosis of disease or other conditions or for determining the state of health, to cure, mitigate, treat, or prevent disease. This includes reagents, calibrators, control materials, specimen receptacles, software, and related instruments.

The in-vitro diagnostics market is segmented into Enzyme-Linked Immunosorbent Assay (ELISA), Radioimmunoassay (RIA), Rapid tests, Enzyme-Linked Immunospot (Elispot) Assay and others are some of the immunoassay techniques in the IVD market. Basic Metabolic Panel, Electrolyte Panel, liver Panel, Lipid Profile, Renal Profile and Thyroid function panel and specialty chemical tests are some of the clinical chemistry technologies. Polymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification Technology (INAAT), Microarray, Hybridization, DNA Sequencing & Next-Generation Sequencing and others are some of the molecular diagnostics market. Along with these, clinical microbiology, hematology, coagulation and hemostasis and others are the type of the IVD technologies in the market.

Among technologies in in-vitro diagnostics market, immunochemistry techniques accounted for the largest share in 2016 growing at mid range single digit CAGR and molecular diagnostics is expected to grow at high single digit CAGR from 2016-2023.

Request Sample Report @ https://www.wiseguyreports.com/sample-request/1324587-in-vitro-diagnostics-ivd-global-market-forecast-to-2023

By application, the in-vitro diagnostics global market is segmented into oncology, diabetes, cardiology, nephrology, transplantation technology, genetic testing, autoimmune diseases, drug testing, infectious diseases and others. Infectious diseases held the largest revenue in 2016 and transplantation diagnostics application is expected to grow at double digit CAGR from 2016-2023.

By product type, the market is segmented into reagents, instruments, software and services. The reagents segment accounted for the largest revenue in 2016, and is expected to grow at mid-range single digit CAGR from 2016 to 2023.

By sample type, the market is segmented into blood, urine, saliva and others. The blood segment accounted for the largest revenue in 2016, and is expected to grow at mid range single digit CAGR from 2016 to 2023.

By end-users, the market is segmented into laboratories, hospitals, academic, and home care. The hospitals end user segment accounted for the largest revenue in 2016, home healthcare is fastest growing segment during the forecasting period.

By geography, the market is segmented into North America, Europe, Asia-Pacific and Rest of World. North America holds the largest market share in 2016, followed by Europe and Asia. The APAC regions tend to be an emerging market with an opportunity for growth with a highest CAGR from 2016-2023 and are likely to be a destination of investment for new investors in the in-vitro diagnosis market.

Growing healthcare expenditure in the emerging markets, strong demand for technologically advanced testing methods for disease diagnosis, increasing adaptation of point of care testing, increasing incidences of chronic lifestyle diseases are some of the important driving factors for this market. It is also seen that there is an increase in the number of clinical laboratories with improved infrastructure in many developed countries which could further push the diagnostics market in these regions. However, Lack of proper reimbursement policies in the developing countries and stringent regulatory framework are the main factors hampering the growth of the IVD market.

The in-vitro diagnostics global market is a competitive and all the active players in this market are involved in innovating new and advanced products to maintain their market shares. The key players in the in-vitro diagnostics global market include Abbott Laboratories (U.S.), Becton Dickinson (U.S.), Bio-Rad laboratories (U.S.), BioMerieux (France), Danaher Corporation (U.S.), Hoffmann-la Roche (Switzerland), Siemens AG (Germany), Carlyle Group (Ortho Clinical Diagnostics) (U.S.), Johnson and Johnson (U.S.), Sysmex Corporation (Japan), ThermoFisher Scientific (U.S.), and Hologic Inc (U.S.).

The report provides an in depth market analysis of the above mentioned segments across the following regions:

North America
Europe
Asia-Pacific
Rest of the World (RoW)
…CONTINUED

Buy this Report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=1324587

Contact Us:
NORAH TRENTD
Partner Relations & Marketing Manager
sales@wiseguyreports.com